Schizophrenia Relapse: Warning Signs, Prevention, and Care
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Schizophrenia relapse means a clinically meaningful return or worsening of psychotic symptoms or associated deterioration after a period of improvement or relative stability in a person with established schizophrenia. Changes may develop gradually, and early warning signs can include disrupted sleep, rising suspiciousness, anxiety, irritability, withdrawing from everyday activities, declining self-care, and a return or intensification of hallucinations or delusions. The appropriate response is to compare the change with the person's usual baseline, contact the treating team early, review possible medical and treatment-related contributors, and use an individualized relapse or crisis plan. A warning sign is a reason for assessment, not proof that relapse is inevitable. NIMH: Schizophrenia · NICE CG178
The immediate priority is safety. New severe confusion, fever or other signs of acute illness, suicidal intent, command hallucinations associated with danger, inability to obtain food or fluids, extreme agitation, or marked immobility and unresponsiveness require urgent medical evaluation. Sudden changes in mental status can reflect medical illness, intoxication, medication effects, delirium, or another condition rather than a recurrence of schizophrenia. When there is imminent danger, use local emergency services; in the United States, 911 is appropriate for immediate medical emergencies and 988 provides suicide and crisis support. NIMH: Understanding Psychosis
What Counts as a Schizophrenia Relapse?
In clinical practice, relapse describes worsening sufficient to matter for symptoms, functioning, distress, safety, or the need to change care. Research studies use different definitions, including specified increases on symptom scales, hospital admission, emergency treatment, or clinician judgment. This variation explains why published relapse rates cannot be applied mechanically to any one person. Someone can have residual voices or unusual beliefs while remaining clinically stable; the important question is whether experiences or functioning have changed from their established pattern.
Relapse is a feature of the course of an existing disorder. It should be distinguished from a first episode of psychosis, an isolated psychotic symptom, a schizophrenia-spectrum diagnosis that has not yet been established, and a clinical high-risk state before psychosis. The schizophrenia overview explains the wider diagnosis; the schizophrenia-spectrum guide explains related conditions and longitudinal assessment.
A return of voices, for example, may be part of relapse if they become more frequent, distressing, directive, or difficult to manage after remission. But hearing a voice once, particularly in a complex medical or sleep context, does not establish schizophrenia. Similarly, deterioration in motivation may result from depression, medication sedation, substance exposure, physical illness, or social stress. Clinicians assess change and its competing explanations rather than diagnosing from a checklist. NIMH: Understanding Psychosis
Early Warning Signs of Schizophrenia Relapse
Early warning signs are changes that sometimes occur before an acute worsening of psychotic symptoms. They are often easier to identify when compared with the person's previous episodes and their recent stable pattern. In a systematic review of 72 studies involving 6,903 participants, sleep, mood, and suspiciousness emerged as important antecedents to symptom worsening. Across the early-warning approaches studied, pooled sensitivity for relapse prediction was 71% and specificity 64%, indicating that warning signs are informative but far from definitive. Gleeson et al., Clinical Psychology Review
Changes in sleep and daily rhythm
Difficulty falling asleep, shorter sleep, staying awake overnight, sleeping at unusual hours, or marked changes in daily structure may precede worsening for some people. Sleep changes are common across many conditions, however, and may also reflect shift work, stress, physical problems, stimulant use, or changes in medication. Recording the duration of the change and accompanying symptoms is more useful than treating one poor night of sleep as a prediction. Gleeson et al.
Rising suspiciousness, uneasiness, or unusual meaning
A person may increasingly fear that ordinary events have special or threatening meanings, become uneasy around familiar people, or feel watched or talked about. The distinction between a distressing thought and a delusion depends on its conviction, context, alternative explanations, and clinical assessment. Avoid confrontational attempts to prove a belief false; listen to the distress, describe observable changes, and seek collaborative review. NIMH: Understanding Psychosis
Mood, anxiety, irritability, and agitation
Before deterioration, some people report feeling unusually tense, fearful, frustrated, overwhelmed, or emotionally unsettled. Other people notice withdrawal, reduced pleasure, or difficulty coping with ordinary demands. These experiences require evaluation in context because mood episodes, trauma reactions, sleep loss, and medical conditions can produce similar changes. Gleeson et al.
Concentration, communication, and daily functioning
Difficulty following conversations, organizing decisions, keeping appointments, preparing meals, attending work or classes, or carrying out familiar routines may indicate change. A relative may notice confusing speech, losing the thread of conversation, or neglecting hygiene. The person's account of whether these changes feel different from their usual cognitive or negative symptoms is central. NIMH: Schizophrenia
Changes in hallucinations, delusions, or thought organization
More intrusive voices, newly compelling delusional interpretations, worsening thought disorganization, or behavior influenced by psychotic experiences can signal that deterioration is already underway. Assessment should ask about subjective distress, the influence of voices or beliefs on choices, ability to sleep and eat, and safety. Hallucinations and delusions can arise in different clinical contexts, so a significant new presentation warrants diagnostic and medical reassessment even when a schizophrenia diagnosis already exists. NICE CG178
Changes in treatment engagement or substance exposure
Missed prescriptions, delayed injections, stopping appointments, or taking medication differently than prescribed may increase relapse vulnerability; equally, side effects may explain why treatment has become difficult to continue. Alcohol, cannabis, stimulants and other substances can complicate symptoms and treatment, while intoxication or withdrawal may have independent clinical effects. Ask what changed and what support is needed instead of assuming deliberate nonadherence or blaming the person. NICE CG178
How Accurate Are Relapse Warning Signs?
Warning signs do not provide a personalized probability calculator. The pooled sensitivity and specificity from the 2024 Gleeson review combine different populations, observation periods, definitions of relapse, and monitoring methods. A sign may be present without a later relapse, and relapse sometimes occurs without a recognizable warning period. A single sign can also have a different meaning across individuals. Gleeson et al.
The strongest use of monitoring is longitudinal and collaborative: document the individual's typical early changes, identify a trusted clinician or contact, and agree in advance what response the changes should trigger. Monitoring should be proportional, voluntary where possible, and helpful rather than intrusive. A Cochrane review found possible reductions in relapse and rehospitalization in studies of early-warning-sign interventions, but rated the evidence very low quality and noted that the intervention was often bundled with other psychological care. Monitoring alone therefore should not be presented as a proven substitute for ongoing treatment. Cochrane early-signs review
What to Do When Early Signs Appear
First: compare changes with the person's baseline
Write down what changed, when it began, how long it has lasted, whether it affects sleep or functioning, and whether similar patterns came before earlier episodes. Include the person's own interpretation and ask what they find worrying or helpful. A record might say, for example, that sleep has fallen substantially over several nights and that familiar situations now feel threatening. A description of behavior and distress is more useful for clinical assessment than declaring that the person is relapsing.
Second: contact the treating team early
Use the psychiatrist, mental health clinician, case manager, community service, or early intervention program named in the care plan. Explain the observable changes and ask how soon assessment is needed. A person with a documented crisis plan should use its specified contact and escalation pathway. NICE explicitly advises referring to the crisis section of the care plan when relapse is suspected and considering contact with the named clinician or care coordinator. NICE CG178, relapse and re-referral
Third: review medications and health factors with a clinician
A medication review may consider missed doses or appointments, emerging adverse effects, recent dose changes, drug interactions, physical illness, recent substance use, sleep disruption, and whether the existing treatment remains effective. Medication changes, extra doses, stopping medication, and restarting after interruption should be decided with an appropriate prescriber. Some drugs require specific retitration after a break; clozapine interruption is one important example. Do not use a home relapse plan as permission to adjust prescriptions independently. APA schizophrenia guideline · NICE CG178
Fourth: reduce avoidable strain without withdrawing needed care
Protect opportunities for sleep, regular meals, predictable routines, and calm communication while keeping access to clinical services and supportive relationships. Ask whether a work, study, or social demand can temporarily be adjusted. Avoid making the person responsible for preventing symptoms simply by relaxing, sleeping, or trying harder. Supportive daily routines are valuable parts of care, but serious deterioration still requires professional evaluation.
Fifth: reassess promptly if the situation escalates
If hallucinations or delusions intensify, thinking becomes markedly disorganized, basic needs cannot be met, or suicidal thoughts or severe behavioral changes emerge, seek same-day urgent clinical assessment or emergency care according to severity. People in acute crisis may need community crisis services, emergency department assessment, or inpatient treatment. Which setting is appropriate depends on safety, medical stability, available support, and the person's preferences. NICE CG178, acute episodes and crisis care
When Is It an Emergency?
Seek immediate emergency medical help for imminent risk of suicide or serious self-harm, threats with credible immediate danger, inability to remain safe, severe disorientation or reduced consciousness, seizures, serious injury, fever with severe stiffness or confusion, or profound inability to care for basic physical needs. Marked immobility, mutism, unusual posturing, and abnormal responsiveness can indicate catatonia or other acute medical problems and require urgent examination. Sudden onset in an older person or in association with infection, intoxication, withdrawal, neurological signs, or medication change makes medical evaluation particularly important.
A person experiencing psychosis may be frightened or confused. Speak clearly, use a quiet environment, offer practical choices, avoid crowding or escalating arguments, and explain the immediate steps being taken. Ask directly about suicidal thoughts when concerned; involve emergency services when safety cannot be maintained. In the United States, call 911 for an immediate life-threatening emergency or 988 for suicide and crisis support. Outside the United States, use local emergency and crisis pathways. NIMH: Understanding Psychosis
What Can Trigger or Contribute to Relapse?
Relapse arises through multiple interacting influences, and episodes may occur even when treatment is followed carefully. Relevant contributors include insufficient control of psychotic symptoms, interruptions in effective medication, adverse effects that make treatment intolerable, sleep disruption, co-occurring substance use, difficult life events, inconsistent access to care, and untreated physical or psychiatric conditions. These are possible contributors rather than a checklist for assigning a single cause. NICE CG178
Medication interruptions deserve particular attention because clinical trials consistently find greater relapse risk after discontinuation of effective maintenance antipsychotic treatment. Yet reasons for interruption are often complex: metabolic effects, emotional blunting, movement symptoms, sexual effects, sedation, cost, access barriers, misunderstanding about treatment, and preferences for autonomy can all be important. Sustainable treatment requires listening to those concerns and adapting care where possible. Ceraso et al., Cochrane systematic review · NIMH: Schizophrenia
A new apparent psychotic episode can instead be related to mania, depression with psychotic features, delirium, neurological illness, medication effects, or substance intoxication or withdrawal. A person can also experience more than one condition at the same time. If the pattern is unfamiliar, unusually rapid, accompanied by new medical signs, or predominantly mood-related, clinicians should reconsider the diagnosis and differential rather than assume every episode is schizophrenia relapse. For one neighboring comparison, see Schizophrenia vs. Bipolar Disorder.
Evidence-Based Schizophrenia Relapse Prevention
Maintenance antipsychotic treatment and shared decisions
For people with established schizophrenia who have responded to antipsychotic medication, continuing an effective maintenance regimen is among the best-supported strategies for reducing relapse. A Cochrane systematic review of 75 randomized trials with 9,145 participants found lower relapse risk with maintenance treatment than with discontinuation or placebo. At one year, relapse occurred in 24% of participants assigned to maintenance medication and 61% assigned to discontinuation or placebo in the relevant pooled trials; these are study-group results, not a prediction for a particular patient. The review also found reductions in hospitalization but increased rates of some adverse effects. Ceraso et al., Schizophrenia Bulletin
Duration, medication choice, dose, and monitoring are individualized. Decisions consider prior episodes, previous response, functioning, values, pregnancy or other medical considerations where relevant, adverse effects, and the consequences of recurrence. Routine intermittent medication only when early signs appear is generally not recommended as a replacement for maintenance care. When treatment reduction or discontinuation is agreed, NICE recommends gradual withdrawal, regular monitoring, and continued relapse surveillance for at least two years after withdrawal. NICE CG178, maintenance treatment
Prescribers should also monitor physical health: weight and metabolic indicators, glucose or HbA1c, lipids, blood pressure, movement problems, relevant cardiac risks, and other treatment-specific safety measures. A preventive regimen that produces intolerable adverse effects is unlikely to meet a person's goals; options include adjustment, switching, management of adverse effects, and appropriate psychosocial support. NICE CG178
Long-acting injectable antipsychotics
Long-acting injectable antipsychotics can be considered when someone prefers injections over daily tablets, when missed oral doses are a recurring difficulty, or when continuity of treatment is a priority. They do not eliminate side effects, relapse risk, or the need for shared decisions. A large 2022 network meta-analysis supports the effectiveness of oral and injectable antipsychotics for maintenance treatment, although comparisons between specific preparations and settings differ. A 2024 systematic review of early-phase schizophrenia-spectrum disorders did not find an overall statistically significant advantage of injections over oral agents in its primary pooled head-to-head comparison, illustrating the importance of population and study design. World Psychiatry network meta-analysis · Early-phase LAI systematic review
Family psychoeducation and family intervention
Family interventions can support relapse prevention by improving understanding, communication, collaborative problem-solving, and access to timely care. A 2022 systematic review and network meta-analysis found that family intervention models reduced relapse relative to usual care across several comparisons; certainty varied, and education-focused approaches were useful. This evidence supports making family support available without turning relatives into monitors or blaming relationships for a person's illness. Rodolico et al., The Lancet Psychiatry00437-5)
NICE recommends offering family intervention to families in close contact with a person with schizophrenia, including those who have recently experienced relapse or remain at risk. Family work should respect confidentiality and the person's wishes about sharing information, and may include crisis-management planning and negotiated problem-solving. Family participation can include a chosen friend or supporter where the individual's care arrangements allow. NICE CG178
Cognitive behavioral therapy for psychosis
Cognitive behavioral therapy for psychosis, or CBTp, can help people understand patterns of distress, develop coping strategies for voices and unusual beliefs, explore interpretations, and support functioning and recovery goals. It is ordinarily offered as part of a comprehensive plan rather than as an independent guarantee against relapse. NICE recommends CBT in acute and ongoing phases and describes a structured, individually delivered treatment. NICE CG178
Coordinated and recovery-oriented community care
Reliable follow-up with a clinician, medication access, help with housing or employment, supported education, peer support, attention to physical health, and assistance with substance use or depression can all matter. After a first episode, coordinated specialty care integrates psychiatric treatment, psychotherapy, family education, and vocational or educational support. The precise package should reflect the person's needs and available services; stable participation in meaningful life activities is a legitimate treatment goal alongside reducing psychotic symptoms. NIMH: Schizophrenia · VA/DoD guideline
Digital monitoring and early warning sign tools
Smartphone diaries and symptom alerts may help people record patterns and communicate with clinicians, but digital prediction is an evolving evidence area. In the EMPOWER study, a blended digital intervention with peer support and clinical triage was feasible, and several exploratory outcomes were encouraging. Its investigators explicitly cautioned that this feasibility trial could not establish clinical effectiveness. Monitoring works best when the person controls participation and knows who responds to alerts, what data are collected, and how emergencies are handled. EMPOWER feasibility trial
How to Make a Personal Schizophrenia Relapse Prevention Plan
A written plan is most useful when developed during a relatively stable period with the person, their treating clinician, and chosen supporters. It should be accessible, revisited after meaningful changes, and tailored to earlier experiences rather than copied from a generic template. The following structure organizes clinical discussion; it is not a prescription or emergency substitute. NICE care planning and crisis recommendations
1. Record the person's stable baseline
Describe usual sleep and daily rhythm, ongoing symptoms if any, expected functioning, the level of support the person wants, preferred communication, routine appointments, and medications as currently prescribed. A baseline helps distinguish change from longstanding difficulties.
2. Identify personal early warning signs
List observable and self-reported changes that preceded earlier episodes: for example, several nights of unusually little sleep, renewed fear of strangers, increasing difficulty concentrating, or returning voices that become distressing. Also list signs that have often appeared without relapse, to reduce overinterpretation.
3. Set graded responses and contact information
Document who should be contacted for mild deterioration, how to obtain a prompt psychiatric review, what constitutes an urgent same-day assessment, and the nearest emergency pathway. Record contact details, after-hours coverage, and practical barriers such as transportation or communication difficulties. The plan can specify consent for contacting particular family members or supporters.
4. Include medication, medical, and daily-life reviews
Record medication names and prescribers, pharmacy access, relevant adverse effects, allergies, other health conditions, and any known reasons treatment was interrupted previously. Include sleep, substance exposure, physical symptoms, and current stressors for clinician review. Avoid pre-authorized self-directed extra dosing unless a licensed prescriber has provided a specific individualized prescription and written instructions.
5. Specify preferences for support and crisis care
Ask what helps when symptoms intensify: quiet conversation, text instead of telephone contact, a trusted person joining an appointment, assistance with meals, or a particular service. Include de-escalation preferences, sensory concerns, privacy needs, and any advance psychiatric care instructions or legal arrangements applicable locally. The person's agency and preferences should remain visible even when urgent assessment is necessary.
6. Agree on follow-up and review
A plan needs a named person or service responsible for follow-up, not merely a list of phone numbers. Revise it after a relapse, a major medication change, moving to a new care system, or a change in support relationships. Document what actually happened and whether the warning signs and responses were helpful.
How Families and Friends Can Help
Start by asking what the person has noticed, how they are sleeping, what feels difficult, and what kind of help they want. Describe concrete changes without arguing over whether an experience is real. Useful phrases include: 'I've noticed you've slept very little this week and seem distressed; would you like me to help contact your clinician?' People may fear another hospital stay or loss of autonomy, so clarity about what happens after asking for help matters.
Offer practical assistance with appointments, transportation, prescriptions, groceries, or a calmer environment when requested. Avoid surveillance, threats, shaming, or automatic attribution of every emotion and disagreement to illness. A relative can share observations with a clinical team even if confidentiality limits what the team can disclose in return. Clinicians and families should discuss consent and information-sharing arrangements early. NICE CG178, support for carers
Caregiving can be tiring and emotionally complex. Families benefit from their own education and support, including instruction about the recovery possibilities of schizophrenia and what to do in a crisis. Professionals should make room for the concerns of both the person living with schizophrenia and those providing care. Rodolico et al.00437-5)
If Relapse Happens: Treatment and Recovery After an Episode
A relapse may require prompt review of the diagnosis, medication regimen, medical causes, and immediate safety. NICE recommends offering antipsychotic treatment or reviewing existing medication together with psychological interventions for acute recurrence, taking prior response and adverse effects into account. A higher level of care is appropriate when safety or severity exceeds what outpatient support can provide. Hospitalization is one possible intervention, not a definition of relapse. NICE CG178
After acute symptoms improve, follow-up should address the person's account of what happened, treatment choices, physical health, sleep, social recovery, and practical disruption to work, education, or relationships. The plan should identify what helped, what felt harmful, whether medication effects or access barriers contributed, and how future contact with services can be made easier. A relapse is not a verdict on the individual's long-term future, and recovery can include meaningful improvement in symptoms, quality of life, autonomy, participation, and relationships. NIMH: Schizophrenia
Repeated or persistent symptoms despite adequate treatment require a specialist review of the diagnosis, medication use and tolerability, co-occurring conditions, and available interventions. Clozapine is an evidence-based option for treatment-resistant schizophrenia under specialist prescribing and monitoring; it is not a routine do-it-yourself relapse medication. Decisions about changing therapies should account for potential benefits, medication-specific risks, physical monitoring requirements, and the person's goals. APA schizophrenia guideline · NICE CG178
Questions People Commonly Ask
Can schizophrenia relapse after years of stability?
Yes. Psychotic symptoms can recur after a long period of improvement, although individual course and future risk vary. A change deserves evaluation rather than an assumption that previous progress has been lost.
Does a poor night of sleep mean relapse is beginning?
No. Sleep disturbance is an important possible early sign, especially if it matches a person's previous relapse pattern and occurs alongside other changes. It is common for many other reasons, and early warning signs have limited predictive accuracy. Gleeson et al.
Is hearing a voice again always a relapse?
No. Assess change from baseline, frequency, distress, conviction, influence on behavior, and possible medical or contextual explanations. Some people experience residual hallucinations while functioning well; others need prompt evaluation when voices become markedly more intense or risky. NIMH: Understanding Psychosis
Can relapse happen while someone is taking medication?
Yes. Antipsychotic medication reduces risk on average but does not guarantee that no episode will occur. Clinicians may need to review response, adverse effects, medical health, sleep, substance use, and treatment continuity before changing a plan. Ceraso et al.
Should medication be stopped when symptoms improve?
Improvement is a reason to review the treatment plan with a prescriber, not to stop medication without a discussion. Withdrawal increases relapse risk on average; when reduction is chosen, it requires an individualized plan with gradual changes and sustained monitoring. NICE CG178
Can family involvement prevent relapse?
Structured family psychoeducation and family interventions can reduce relapse risk in research and improve coordinated support, especially alongside treatment and social care. Benefits vary, and the form of participation should respect the person's preferences and confidentiality. Rodolico et al.00437-5)
How long does recovery from a relapse take?
There is no universal timeline. Changes in hallucinations or delusions, sleep, cognition, daily functioning, and confidence may improve at different rates. The clinical team should set concrete follow-up goals and monitor functioning and quality of life as well as symptoms.
What if the person refuses an appointment?
Ask why care is difficult: fear, prior negative experiences, transportation, cost, side effects, distress, or unfamiliarity with the team. Offer collaborative choices and contact the existing service for guidance. If the person cannot remain safe or has acute medical symptoms, emergency assessment may be necessary according to local clinical and legal standards.
The Essential Clinical Takeaway
Relapse prevention is strongest when the person can recognize meaningful changes from their own stable baseline, access timely professional assessment, use an effective and tolerable long-term treatment plan, and receive practical, respectful support. The evidence for maintenance antipsychotics and structured family interventions is stronger than the evidence for predicting an individual relapse from warning signs alone. Accurate early recognition should lead to collaborative care rather than fear, blame, unsupervised medication changes, or self-diagnosis. Ceraso et al. · Rodolico et al.00437-5) · Gleeson et al.
Related Articles
Schizophrenia: Symptoms, Causes, Diagnosis, Treatment, and Recovery — the main overview of diagnosis, treatment and long-term functioning.
Schizophrenia Spectrum Disorders: Types, Differences, and Clinical Diagnosis — clarifies different diagnoses and clinical presentation.
Schizophrenia vs. Schizoaffective Disorder: Key Diagnostic Differences — the longitudinal relationship between mood episodes and psychosis.
Schizophrenia vs. Bipolar Disorder: Psychosis, Mood, and Diagnosis — why psychotic symptoms are not specific to schizophrenia.
References
American Psychiatric Association. (2020). The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. APA clinical guidelines
Ceraso, A., Lin, J. J., Schneider-Thoma, J., et al. (2022). Maintenance treatment with antipsychotic drugs in schizophrenia: A Cochrane systematic review and meta-analysis. Schizophrenia Bulletin, 48(4), 738–740. DOI
Gleeson, J. F., McGuckian, T. B., Fernandez, D. K., et al. (2024). Systematic review of early warning signs of relapse and behavioural antecedents of symptom worsening in people living with schizophrenia spectrum disorders. Clinical Psychology Review, 107, 102357. DOI
Gumley, A. I., Bradstreet, S., Ainsworth, J., et al. (2022). Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: The EMPOWER feasibility cluster RCT. Health Technology Assessment, 26(27), 1–174. DOI
Morriss, R., Vinjamuri, I., Faizal, M. A., Bolton, C. A., & McCarthy, J. P. (2022). Training to recognise the early signs of recurrence in schizophrenia. Cochrane Database of Systematic Reviews, 2022(4), CD005147. DOI
National Institute for Health and Care Excellence. (2014, updated). Psychosis and schizophrenia in adults: Prevention and management (CG178). NICE
National Institute of Mental Health. (n.d.). Schizophrenia. NIMH
National Institute of Mental Health. (n.d.). Understanding psychosis. NIMH
Ostuzzi, G., Bertolini, F., Tedeschi, F., et al. (2022). Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: A network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry, 21(2), 295–307. DOI
Rodolico, A., Bighelli, I., Avanzato, C., et al. (2022). Family interventions for relapse prevention in schizophrenia: A systematic review and network meta-analysis. The Lancet Psychiatry, 9(3), 211–221. DOI
U.S. Department of Veterans Affairs and U.S. Department of Defense. (2023). Management of first-episode psychosis and schizophrenia: Clinical practice guideline. VA/DoD
Vita, G., Tavella, A., Ostuzzi, G., et al. (2024). Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: A systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology, 14, 20451253241257062. DOI